2020-004703-14
A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus
Sanofi-Aventis Recherche & Développement·EU Clinical Trials RegisterCompleted
Study focus
- Disease/Condition
- Cutaneous Lupus Erythematosus
Sponsor & location
- Primary sponsor
- Sanofi-Aventis Recherche & Développement
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Participants are excluded from the study if any of the following criteria apply:
ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2020-004703-14
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2020-004703-14 through Pure Global AI's free database. This phase not specified trial is sponsored by Sanofi-Aventis Recherche & Développement and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.